MX2022010306A - Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras). - Google Patents

Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras).

Info

Publication number
MX2022010306A
MX2022010306A MX2022010306A MX2022010306A MX2022010306A MX 2022010306 A MX2022010306 A MX 2022010306A MX 2022010306 A MX2022010306 A MX 2022010306A MX 2022010306 A MX2022010306 A MX 2022010306A MX 2022010306 A MX2022010306 A MX 2022010306A
Authority
MX
Mexico
Prior art keywords
antibodies
kras
relates
epitopes
mutant forms
Prior art date
Application number
MX2022010306A
Other languages
English (en)
Inventor
Carolina Trkulja
Owe Orwar
Max Davidson
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2002556.5A external-priority patent/GB202002556D0/en
Priority claimed from GBGB2101780.1A external-priority patent/GB202101780D0/en
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2022010306A publication Critical patent/MX2022010306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a ciertas formas mutantes oncogénicas de KRAS; la invención también se refiere a ciertos epítopos de las formas mutantes oncogénicas de KRAS; la invención también se refiere a inmunoconjugados y composiciones que comprenden tales anticuerpos; la invención también provee métodos de producción de tales anticuerpos; la invención provee además el uso de tales anticuerpos con fines terapéuticos, por ejemplo en el tratamiento de cáncer.
MX2022010306A 2020-02-24 2021-02-24 Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras). MX2022010306A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002556.5A GB202002556D0 (en) 2020-02-24 2020-02-24 Epitopes and antobodies
GBGB2101780.1A GB202101780D0 (en) 2021-02-09 2021-02-09 Epitopes and Antibodies
PCT/EP2021/054614 WO2021170684A1 (en) 2020-02-24 2021-02-24 Kras epitopes and antibodies

Publications (1)

Publication Number Publication Date
MX2022010306A true MX2022010306A (es) 2022-11-14

Family

ID=74867498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010306A MX2022010306A (es) 2020-02-24 2021-02-24 Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras).

Country Status (11)

Country Link
US (1) US20230109318A1 (es)
EP (1) EP4110388A1 (es)
JP (1) JP2023514423A (es)
KR (1) KR20220157400A (es)
CN (1) CN115443153A (es)
AU (1) AU2021227406A1 (es)
BR (1) BR112022016643A2 (es)
CA (1) CA3171833A1 (es)
IL (1) IL295788A (es)
MX (1) MX2022010306A (es)
WO (1) WO2021170684A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230084524A (ko) * 2020-10-02 2023-06-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체
WO2022219152A1 (en) * 2021-04-16 2022-10-20 Oblique Therapeutics Ab Kras antibodies
KR20230068628A (ko) * 2021-11-11 2023-05-18 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR20230068627A (ko) * 2021-11-11 2023-05-18 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
CN116640218B (zh) * 2023-06-01 2024-06-04 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种靶向kras g12v单链抗体片段、嵌合抗原受体car及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
KR101602870B1 (ko) * 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
CN108440647A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250269A (zh) * 2018-04-02 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108484731A (zh) * 2018-04-02 2018-09-04 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440646A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440648A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用

Also Published As

Publication number Publication date
EP4110388A1 (en) 2023-01-04
WO2021170684A1 (en) 2021-09-02
CA3171833A1 (en) 2021-09-02
AU2021227406A1 (en) 2022-09-29
KR20220157400A (ko) 2022-11-29
CN115443153A (zh) 2022-12-06
US20230109318A1 (en) 2023-04-06
JP2023514423A (ja) 2023-04-05
BR112022016643A2 (pt) 2022-10-11
IL295788A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
MX2022010306A (es) Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras).
WO2017219029A8 (en) COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2018015683A (es) Composiciones y métodos para el agotamiento de células.
MX2022009936A (es) Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
WO2019084057A3 (en) Compositions and methods for the depletion of cd117+ cells
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
CR20200463A (es) Anticuerpos
MX2022005221A (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
ZA201907225B (en) Treatment of her2 positive cancers
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2020011176A (es) Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
MX2023002001A (es) Anticuerpos anti-par-2 y metodos de uso de los mismos.
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2021001058A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer.
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2022015475A (es) Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma.